← Back to patent-cliff list
OD-07656
Tier C — Watch / tradeOD-07656
Odyssey Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：RIPK2
Indications (approved)：Ulcerative colitis, Crohn's disease, Inflammatory bowel disease, 遗传性自身炎性疾病, Spondyloarthritis
Regional status
US
-
EU
Phase II
2025-06-02
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of OD-07656?
Approved indications include: Ulcerative colitis, Crohn's disease, Inflammatory bowel disease, 遗传性自身炎性疾病, Spondyloarthritis.
When does the OD-07656 patent expire?
No public expiry year is available for OD-07656 yet; this page updates once verified.
How do I get a quote for OD-07656 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30